Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care
dc.contributor.author | Apostolova, Liana G. | |
dc.contributor.author | Haider, Janelle M. | |
dc.contributor.author | Goukasian, Naira | |
dc.contributor.author | Rabinovici, Gil D. | |
dc.contributor.author | Chetelat, Gael | |
dc.contributor.author | Ringman, John M. | |
dc.contributor.author | Kremen, Sarah | |
dc.contributor.author | Grill, Joshua | |
dc.contributor.author | Restrepo, Lucas | |
dc.contributor.author | Mendez, Mario F. | |
dc.contributor.author | Silverman, Daniel H. | |
dc.contributor.department | Department of Neurology, IU School of Medicine | en_US |
dc.date.accessioned | 2017-05-01T19:32:52Z | |
dc.date.available | 2017-05-01T19:32:52Z | |
dc.date.issued | 2016-12-18 | |
dc.description.abstract | INTRODUCTION: The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. METHODS: Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. RESULTS: Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. DISCUSSION: The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases. | en_US |
dc.identifier.citation | Apostolova, L. G., Haider, J. M., Goukasian, N., Rabinovici, G. D., Chételat, G., Ringman, J. M., … Silverman, D. H. (2016). Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring, 5, 15–22. http://doi.org/10.1016/j.dadm.2016.12.001 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/12391 | |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/j.dadm.2016.12.001 | en_US |
dc.relation.journal | Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
dc.source | PMC | en_US |
dc.subject | Alzheimer's disease (AD) | en_US |
dc.subject | Amyloid | en_US |
dc.subject | Appropriate use criteria (AUC) | en_US |
dc.subject | Mild cognitive impairment (MCI) | en_US |
dc.subject | Positron emission tomography (PET) | en_US |
dc.title | Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care | en_US |
dc.type | Article | en_US |